What's new? Log in Free sign up

Filing search / Intellia Therapeutics, Inc. / "Social"

Search information

Intellia Therapeutics, Inc.

Companies

"Social"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

74 results

Newest first Best match first

NTLA Intellia Therapeutics, Inc.

to encourage social distancing, promote and protect health and physical well-being and/or intended to limit the spread of Infectious Conditions (as defined … and regulations relating to the use of the Project Amenities and/or rules and regulations which are intended to encourage social distancing, promote

27 Feb 25

4:03pm

NTLA Intellia Therapeutics, Inc.

, and promotional activities involving the internet and social media platforms. Discovery of previously unknown problems or the failure to comply … values—ONE, EXPLORE, DISRUPT, and DELIVER. Our employee resource groups, including groups focused on mentorship, career development, social activities

27 Feb 25

4:03pm

NTLA Intellia Therapeutics, Inc.

called “tipping”) Material, Nonpublic Information concerning the Company (including by way of social media); or iii.recommend to any other person … the Company (including by way of social media); or iv.do any of the activities described in “i” through “iii” above with respect to a public company

27 Feb 25

4:03pm

NTLA Intellia Therapeutics, Inc.

Quarterly report

cells, could adversely impact public and governmental perceptions regarding the ethics and risks of the CRISPR/Cas9 technology and lead to social … products obsolete. In addition, adverse publicity due to the ethical and social controversies surrounding the therapeutic in vivo use of CRISPR/Cas9, genome

7 Nov 24

4:05pm

NTLA Intellia Therapeutics, Inc.

Quarterly report

regarding the ethics and risks of the CRISPR/Cas9 technology and lead to social or legal changes that could limit our ability to apply the technology … and social controversies surrounding the therapeutic in vivo use of CRISPR/Cas9, genome edited modified cells, or other therapeutics mediums

8 Aug 24

4:06pm

8epysw96hvm abk6uk

Intellia Therapeutics Announces CFO Transition

Quarterly report

9 May 24

4:25pm

v28an0y d9saxfnlqqa

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

pwn 23i8qviiuii

Definitive proxy

29 Apr 24

4:16pm

5rjs1a2jkwu 389akl

Preliminary proxy

16 Apr 24

4:10pm

22 Feb 24

4:02pm

dsrg3ykh3r i1kkw0

Quarterly report

9 Nov 23

4:05pm

z6is95 0utreg7b

Regeneron and Intellia Announce Expanded Research Collaboration

Quarterly report

3 Aug 23

4:13pm

Quarterly report

4 May 23

4:12pm

byv2sw0g6w l0qb

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

3ou82lm k5sz11i9h

Definitive proxy

1 May 23

4:21pm

uttonv7u68dow pcxd

Preliminary proxy

Entry into a Material Definitive Agreement

Prospectus supplement for primary offering

Prev
1
2
3
4
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.